Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-09-12
2006-09-12
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S114000, C514S649000, C514S608000, C514S706000
Reexamination Certificate
active
07105575
ABSTRACT:
The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
REFERENCES:
patent: 3892824 (1975-07-01), Piper et al.
patent: 4656034 (1987-04-01), Sarnoff
patent: 4735210 (1988-04-01), Goldenberg
patent: 4742050 (1988-05-01), Yuhas et al.
patent: 5091180 (1992-02-01), Walker et al.
patent: 5112954 (1992-05-01), Abrams et al.
patent: 5167947 (1992-12-01), Geary
patent: 5217964 (1993-06-01), Edwards et al.
patent: 5424471 (1995-06-01), Kennedy et al.
patent: 5434145 (1995-07-01), Edwards et al.
patent: 5488042 (1996-01-01), Grdnia
patent: 5567686 (1996-10-01), Grdnia
patent: 5591731 (1997-01-01), Kennedy et al.
patent: 5605931 (1997-02-01), Hanson
patent: 5618823 (1997-04-01), Cavalletti et al.
patent: 5776095 (1998-07-01), Goldenberg
patent: 5824664 (1998-10-01), Schein et al.
patent: 5846958 (1998-12-01), Capizzi et al.
patent: 5866591 (1999-02-01), Gatlin et al.
patent: 5869338 (1999-02-01), Grdnia
patent: 5891856 (1999-04-01), Grdnia
patent: 5906984 (1999-05-01), Capizzi et al.
patent: 5919934 (1999-07-01), John et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 5994409 (1999-11-01), Stogniew et al.
patent: 6028114 (2000-02-01), Quash
patent: 6051563 (2000-04-01), Stogniew et al.
patent: 6054622 (2000-04-01), Zhang et al.
patent: 6066688 (2000-05-01), Hausheer
patent: 6075053 (2000-06-01), Hausheer
patent: 6096399 (2000-08-01), Ayer et al.
patent: 6106866 (2000-08-01), Ranny
patent: 6110891 (2000-08-01), Pusztai et al.
patent: 6114394 (2000-09-01), Edwards et al.
patent: 6127351 (2000-10-01), Stogniew et al.
patent: 6218377 (2001-04-01), Stogniew et al.
patent: 6239119 (2001-05-01), Stogniew et al.
patent: 6384259 (2002-05-01), Stogniew et al.
patent: 6407278 (2002-06-01), Stogniew et al.
patent: 6489312 (2002-12-01), Stogniew et al.
patent: 6573253 (2003-06-01), Stogniew
patent: 6586476 (2003-07-01), Stogniew et al.
patent: 2003/0096797 (2003-05-01), Stogniew et al.
patent: WO 89/05637 (1989-06-01), None
patent: WO 88/07942 (1989-09-01), None
patent: WO 95/0700 (1995-03-01), None
patent: WO 97/11666 (1997-04-01), None
patent: WO 99/30705 (1999-06-01), None
Jessica Foster-Nora et al, Am. J. Health-Syst. Pharm., vol. 54, pp. 787-798, Apr. 1, 1997.
Craig Lewis, Drug Safety, vol. 11(3), pp. 153-162, 1994.
Capizzi, R.L., 126CA:83898, 1996.
Savoye et al. 126CA:260996, 1997.
Treskes et al, 117CA:39934, 1992.
Capizzi “The preclinical basis for broad-spectrum selective cytoprotection of Normal tissue from cytotoxic therapies by Amifostine (Ethyol),” European Journal of Cancer , 1996, vol. 32A, Suppl. 4, pp. S5-S16.
RamaKrishnan et al. “N-(2-mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programed cell death,” The Journal of Immunology, 1992, vol. 148, pp. 1817-1821.
Bohuslavizki et al., “Protection of salivary glands by amifostine in patients treated with high dose radioiodine”, Eu. Jour. Cancer 33: S17 (1997).
Fitchner et al., “Effects of amifostine on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas”, Anti-cancer Drugs 8(2): 174-181 (1997).
Foster-Nora et al., “Amifostine for protection from antineoplastic drug toxicity”, Am. Jour. Health-system Pharm. 54(7): 787-800 (1997).
Lewis, “A review of the use of chemoprotectants in cancer chemotherapy”, Drug Safety: An International Journal of Medical Toxicology and Drug Experience 11(3): 153-162 (1994).
Spencer et al., “Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector”, Drugs 50(6): 1001-1031 (1995).
Davidson et al., “Biological characteristics of some improved radioprotectors,”Radiation Sensitizers, 1980 pp. 309-320.
“Drug Information For The Health Care Provider,” 1987,United States Pharmacopeia Dispensing Information, 7thEdition, (1):1217-19.
Hirschel-Scholz et al., 1988, “Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721,”Kidney International, 33:934-941.
NIH Publication No. 89-2141, Revised Nov. 1988.
Petrotti et al., 1992, “Protection from hypoxemia-induced renal dysfunction by the thiophosphate WR-2721,”Kidney International, 41:80-87.
Phillips et al., 1982, “Differential Protection Against Alkylating Agent Injury In Tumors And Normal Tissues,”Radioprotectors and Anticarcinogens, 735-48.
R.L. Capizzi, 1996, “The Preclinical Basis for Broad-spectrum Selective Cytoprotection of Normal Tissues from Cytotoxic Therapies by Amifostine (Ethyol®),”European Journal of Cancer, 32A(4):S5-S16.
Valeriote et al, 1982, “Protection and Potentiation of Nitrogen Mustard Cytoxicity by WR-2721,”Cancer Research, 42:4330-31.
Yuhas et al., 1980, “Treatment of Tumours With The Combination of WR-2721 and Cis-dichloro-diammineplatinum (II) or Cyclophosphamide,”)British Journal of Cancer, 42:574-585.
Zedeii et al., 1991, “Stability of Ethiofos (NSC-29691) In Aqueous Solution and Solid Phase Formulation” (PDD 7184),Pharm. Res.8(10):S-172.
Buntzel et al., “Selective Cytoprotection by Amifostine (A) in the Treatment of Head and Neck Cancer with Simultaneous Radiochemotherapy (RCT),” Eu. Jour. Cancer 33:S189 (1997).
Buntzel et al., “Amifostine in Simultaneous Radiochemotherapy for Head and Neck Cancer,” Otorhinolaryngol Nova 7:204-210 (1997).
Buntzel et al., “Selective Cytoprotection with Amifostine: A New Strategy in Supportive Care of Head and Neck Malignancies,” Otorhinolaryngol Nova 7:276-280 (1997).
MedLmmune Oncology, Inc., Product Information, p. 1-4 (2003).
Alberts David S.
Kaplan Edward H.
Stogniew Martin
Jones Day
Medimmune Oncology Inc.
Wang Shengjun
LandOfFree
Methods for the treatment of neuro- disorders using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of neuro- disorders using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of neuro- disorders using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3529271